Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Aldevron and Ginkgo Bioworks announce mRNA manufacturing ‘breakthrough’

By Brian Buntz | August 10, 2021

Aldevron/GinkgoThe partnership between Aldevron (Fargo, N.D.) and Ginkgo Bioworks (Boston) has resulted in an improvement in the manufacturing yield of the vaccinia capping enzyme (VCE).

VCEs are often used in the production of mRNA vaccines and therapeutics.

The new production protocol is more than 10 times more efficient than the prior process, according to a statement from both firms. The gene therapy company Aldevron will have exclusive rights to the protocol conditions of the manufacturing process. Ginkgo Bioworks specializes in synthetic biology.

“Aldevron’s industry-leading products and services are the foundation for some of the most exciting advances in biological science today,” said Jason Kelly, CEO of Ginkgo Bioworks, in a statement.

Tom Foti, president of Aldevron’s protein business unit, predicted the new production method would “accelerate mRNA therapeutic and vaccine development for manufacturing teams around the world.”

Ginkgo Bioworks is poised to go public via a merger with Soaring Eagle Acquisition Company, a SPAC. Earlier this year, the investment firm Cathie Wood of Ark Invest pegged Ginkgo’s valuation at $15 billion.

Last month, Aldevron revealed a strategic partnership with AavantiBio focused on gene therapies for rare genetic diseases. Under the terms of the partnership deal, Aldevron will manufacture plasmids for AavantiBio’s gene therapy programs.

 

 

Tell Us What You Think! Cancel reply

Related Articles Read More >

Pfizer logo
Pfizer and BioNTech seek EMA authorization for COVID-19 vaccination in young children
Pfizer logo
FDA allows pharmacists to prescribe Paxlovid 
vaccine
Will COVID-19 vaccines be updated by fall? 
COVID-19 vaccine
Young children in U.S. now eligible for COVID-19 vaccination

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards